Results 121 to 130 of about 62,440 (162)

Proton pump inhibitors and osteoporosis

Current Opinion in Rheumatology, 2016
Purpose of review The purpose of the review is to provide an update on recent advances in the evidence based on proton pump inhibitors (PPI) as a possible cause of osteoporosis and osteoporotic fractures. This review focuses, in particular, on new studies published in the last 18 months and a discussion of these findings and ...
Andersen, Bjarne Nesgaard, Johansen, Per Birger, Abrahamsen, Bo   +2 more
openaire   +2 more sources

Proton Pump Inhibitors for Dyspepsia

Digestive Diseases, 2008
Proton pump inhibitors are widely used in many upper gastrointestinal disorders. Dyspepsia is a common problem in primary care and endoscopy is neither feasible nor affordable in the majority of patients. <i>Helicobacter pylori</i> eradication has been shown to be effective, but with the declining prevalence of <i>H.
openaire   +2 more sources

An Overview of Proton Pump Inhibitors

Gastroenterology Nursing, 2003
Proton pump inhibitors are the standard of treatment for acid-related disorders. These disorders include gastroesophageal reflux disease and its complications (i.e., erosive esophagitis and Barrett's esophagus), peptic ulcer disease, Zollinger-Ellison syndrome, and idiopathic hypersecretion.
openaire   +2 more sources

Esomeprazole: a proton pump inhibitor

Expert Review of Gastroenterology & Hepatology, 2009
Proton pump inhibitors (PPIs) are the most potent inhibitors of gastric acid secretion available, and they are effective for treating all acid-related disorders. Esomeprazole is one of several most recent PPIs that became available to the market in 2001.
Ravi, Vachhani, Gregory, Olds, Vic, Velanovich   +2 more
openaire   +2 more sources

Proton pump inhibitors

Current Opinion in Gastroenterology, 2012
This review summarizes adverse effects of potential proton pump inhibitors (PPIs), including nutritional deficiencies (B12 and magnesium), rebound acid hypersecretion, acute interstitial nephritis, gastric carcinoid tumor, cardiovascular risk with clopidogrel and PPI coprescription, bone fractures, enteric infections and pneumonia.
Saman, Chubineh, John, Birk
openaire   +4 more sources

Lansoprazole: A Proton Pump Inhibitor

Annals of Pharmacotherapy, 1996
OBJECTIVE: To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
openaire   +2 more sources

Pharmacogenomics of proton pump inhibitors

Pharmacogenomics, 2004
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are metabolized by cytochrome P450 isoenzyme 2C19 (CYP2C19) in the liver. There are genetic differences that affect the activity of this enzyme. The genotypes of CYP2C19 are classified into three groups: homozygous extensive metabolizer (homEM),
Takahisa, Furuta, Naohito, Shirai, Mitsushige, Sugimoto, Kyoichi, Ohashi, Takashi, Ishizaki   +4 more
openaire   +2 more sources

Proton pump inhibitors

BMJ, 2023
Danny, Jenkins, Ines, Modolell
openaire   +2 more sources

Proton Pump Inhibitors and Mortality

Gastroenterology, 2023
Helge L. Waldum, Reidar Fossmark
openaire   +2 more sources

PROTON PUMP INHIBITORS IN INFANTS

Journal of Pediatric Gastroenterology and Nutrition, 2005
Thomas P. Iarocci, Hiangkiat Tan, Joseph Singer, Barron John, Edith Pilzer, Dinesh Patel, Alan Bakst   +6 more
openaire   +1 more source